Flonoltinib Maleate (JAK inhibitor)

Current understanding

To be populated as evidence accumulates.

2026-04-08 — A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis: cross-connection with flonoltinib-maleate-mpn: Likely duplicate pages for the same agent (Flonoltinib Maleate); should be reconciled/merged. (novelty: 4)
2026-03-04 — Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera: Phase IIa open-label, randomized, parallel-controlled, multicenter trial (trial-early) evaluating flonoltinib maleate tablets in PV patients resistant or intolerant to hydroxyurea or interferon, with a dose-exploration stage (three dose groups, 3 subjects each) followed by an extension stage at 2-3 selected doses; endpoints include safety, efficacy, and pharmacokinetics. (novelty: 4)